Accelerated Biological Aging is Associated With Increased Risk of T2DM in the MASLD Population
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Observational.
- Who it may be relevant to
- Registry conditions: Type 2 Diabetes Mellitus (T2DM), Metabolic Dysfunction-Associated Steatotic Liver Disease, Biological Age. Basic parameters: 20 years — 90 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Accelerated Biological Aging is Associated With Increased Risk of T2DM in the MASLD Population: a Cohort Study
Overview
The association between biological aging and type 2 diabetes mellitus (T2DM) incidence in individuals with and without metabolic dysfunction-associated steatotic liver disease (MASLD) remains unclear.We assessed biological age by calculating phenotypic age (PhenoAge), Klemera-Doubal method (KDMAge), and homeostatic dysregulation (HDAge). To examine the association of biological ageing with the risk of T2DM, cox regression models were conducted. Furthermore, we applied survival analysis, restricted cubic spline models and population attributable fraction (PAF) to further evaluate the association between biological ageing and T2DM incidence.
Interventions
- Other Observational
Observational
Primary outcome measures
- Incidence of onset T2DM [Time frame: through study completion, an average of 3 year]
Eligibility criteria
Inclusion criteria
- Abdominal ultrasound data available in annual health check-up records
- At least one of the following five metabolic indicators recorded annually:
(1) Body mass index (BMI) or waist circumference (2) Blood pressure (3) Serum triglycerides (4) High-density lipoprotein cholesterol (HDL-C) (5) Fasting plasma glucose or glycated hemoglobin (HbA1c)
Exclusion criteria
- Age <20 or >90 years
- Other causes of hepatic steatosis (e.g., alcoholic liver disease or hepatitis B infection)
- Type 2 diabetes mellitus at baseline
- Missing baseline data for any of the following variables: systolic blood pressure, albumin, alkaline phosphatase, blood urea nitrogen, creatinine, glycated hemoglobin (HbA1c), total cholesterol, lymphocyte percentage, white blood cell count, mean corpuscular volume, uric acid, fasting plasma glucose, and red cell distribution width (RDW)
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Study design
- Observational model
- Cohort
Study locations
China · 1 center
- the First Affiliated Hospital of Ningbo University Ningbo, Zhejiang, China, 315000 — Ningbo
Identifiers
NCT: NCT06984510 · 2025-070RS-01 · MR-33-25-026098